Home » Stocks » NUVA

NuVasive, Inc. (NUVA)

Stock Price: $60.33 USD 1.83 (3.13%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $60.50 +0.17 (0.28%) Feb 26, 5:09 PM
Market Cap 3.11B
Revenue (ttm) 1.05B
Net Income (ttm) -37.15M
Shares Out 51.42M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE 24.15
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $60.33
Previous Close $58.50
Change ($) 1.83
Change (%) 3.13%
Day's Open 58.44
Day's Range 56.93 - 62.41
Day's Volume 1,192,898
52-Week Range 28.55 - 67.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 16 hours ago

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

PRNewsWire - 2 days ago

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally...

Zacks Investment Research - 1 week ago

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 weeks ago

SAN DIEGO, Feb. 8, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

PRNewsWire - 3 weeks ago

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 5, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

PRNewsWire - 1 month ago

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

Zacks Investment Research - 1 month ago

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently launched products as well as potential in its U.S. Surgical Support business.

Zacks Investment Research - 2 months ago

The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.

Zacks Investment Research - 2 months ago

The ACP system within NuVasive's (NUVA) C360 portfolio is targeted to reduce common postoperative complications.

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally...

Insider Monkey - 3 months ago

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend mi...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...

Zacks Investment Research - 3 months ago

NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.

Seeking Alpha - 3 months ago

NuVasive, Inc. (NUVA) CEO Chris Barry on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

NuVasive (NUVA) delivered earnings and revenue surprises of 100.00% and 14.09%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally...

Zacks Investment Research - 4 months ago

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally...

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 14, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally...

Zacks Investment Research - 4 months ago

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Zacks Investment Research - 4 months ago

NUVA vs. SRDX: Which Stock Is the Better Value Option?

Other stocks mentioned: SRDX
Zacks Investment Research - 4 months ago

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

Zacks Investment Research - 5 months ago

NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc.

Zacks Investment Research - 5 months ago

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 5 months ago

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- NuVasive, Inc.

Seeking Alpha - 5 months ago

NuVasive's Valuation Prices In An Excessively Bearish Outlook

Zacks Investment Research - 6 months ago

NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.

Seeking Alpha - 6 months ago

NuVasive, Inc. (NUVA) CEO Chris Barry on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

NuVasive (NUVA) delivered earnings and revenue surprises of 18.37% and -0.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 6 months ago

NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

24/7 Wall Street - 6 months ago

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spina...

Other stocks mentioned: ABT, BAX, BSX, EW, GMED, JNJ, MDT, SYK
Zacks Investment Research - 6 months ago

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.

Investors Business Daily - 8 months ago

A Relative Strength Rating upgrade for Nuvasive shows improving technical performance. Will it continue?

Zacks Investment Research - 8 months ago

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 8 months ago

SAN DIEGO, June 4, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Conv...

PRNewsWire - 8 months ago

SAN DIEGO, May 28, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering (the "Offering") of $400.0 million aggregate principal amount of 1.00% Convert...

PRNewsWire - 9 months ago

SAN DIEGO, May 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today that it intends to offer (the "Offering"), subject to market and other considerations, $400.0 million aggr...

Zacks Investment Research - 9 months ago

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

Seeking Alpha - 9 months ago

NuVasive, Inc. (NUVA) CEO Chris Barry on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

NuVasive (NUVA) delivered earnings and revenue surprises of 37.14% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.

The Motley Fool - 10 months ago

What should investors think of this leader in the spinal surgery market?

The Motley Fool - 11 months ago

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Other stocks mentioned: BDX, F, FCAU, GM, JNJ, MDT, PHG, RMD, SNN, SYK, TSLA, WMGI, ZBH
Zacks Investment Research - 11 months ago

Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.

The Motley Fool - 11 months ago

NuVasive's stock is getting unfairly punished by this moody market.

The Motley Fool - 11 months ago

The healthcare companies couldn't sidestep the COVID-19 slump.

Other stocks mentioned: BABY, EXEL

About NUVA

NuVasive, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an inte... [Read more...]

Industry
Medical Devices
Founded
1997
CEO
J. Christopher Barry
Employees
2,800
Stock Exchange
NASDAQ
Ticker Symbol
NUVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for NuVasive stock is "Buy." The 12-month stock price forecast is 60.53, which is an increase of 0.33% from the latest price.

Price Target
$60.53
(0.33% upside)
Analyst Consensus: Buy